{"id":"aeras-402-3-x-10-8-vp","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL4297402","moleculeType":"Small molecule","molecularWeight":"510.52"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"AERAS-402 uses a recombinant adenovirus serotype 35 (Ad35) as a viral vector to deliver TB antigens (Ag85A and TB10.4) intramuscularly, triggering both CD8+ and CD4+ T-cell responses. The vaccine is designed to boost immunity in individuals previously vaccinated with BCG or to provide primary immunization against tuberculosis infection and disease.","oneSentence":"AERAS-402 is a replication-deficient adenovirus vector vaccine that expresses Mycobacterium tuberculosis antigens to stimulate immune responses against tuberculosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:20:01.518Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Tuberculosis prevention (boost vaccination in BCG-primed individuals)"},{"name":"Tuberculosis prevention in HIV-positive individuals"}]},"trialDetails":[{"nctId":"NCT02414828","phase":"PHASE2","title":"A Study to Evaluate the Safety of AERAS-402 in Adults Recently Treated for Pulmonary TB","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-10","conditions":"Tuberculosis","enrollment":72},{"nctId":"NCT02430506","phase":"PHASE1","title":"A Study to Evaluate Safety and Immunogenicity of AERAS-402 Administered in HIV-negative, BCG-vaccinated, QFT (+) and (-) Adults Without Evidence of TB","status":"COMPLETED","sponsor":"Aeras","startDate":"2008-09","conditions":"Tuberculosis","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["AERAS-402"],"phase":"phase_2","status":"active","brandName":"AERAS-402 3 x 10^8 vp","genericName":"AERAS-402 3 x 10^8 vp","companyName":"Aeras","companyId":"aeras","modality":"Biologic","firstApprovalDate":"","aiSummary":"AERAS-402 is a replication-deficient adenovirus vector vaccine that expresses Mycobacterium tuberculosis antigens to stimulate immune responses against tuberculosis. Used for Tuberculosis prevention (boost vaccination in BCG-primed individuals), Tuberculosis prevention in HIV-positive individuals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}